CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.Bruce Ruggeri, Craig A. Dionne, Роберто Пили et al.|PubMed|2003Cited by 124
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cellsWeihua Wan, Mangeng Cheng, Linda R. Weinberg et al.|Blood|2005Cited by 105
A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055Diane E. Gingrich, Robert L. Hudkins, Craig A. Dionne et al.|Journal of Medicinal Chemistry|2003Cited by 74
Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4<i>H</i>-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic AgentRobert L. Hudkins, Bruce Ruggeri, Nadine C. Becknell et al.|Journal of Medicinal Chemistry|2011Cited by 42